TY - JOUR
T1 - Head circumference in infants with nonopiate-induced neonatal abstinence syndrome
AU - Morimoto, Daisaku
AU - Washio, Yosuke
AU - Hatayama, Kazuki
AU - Okamura, Tomoka
AU - Watanabe, Hirokazu
AU - Yoshimoto, Junko
AU - Tsukahara, Hirokazu
N1 - Publisher Copyright:
©
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Background No relationship has been reported between nonopiate neonatal abstinence syndrome (NAS) and anthropometric indices, including head circumference (HC). The purpose of this study was to determine the relationship between maternal nonopioid drug use and HC at birth in neonates with NAS. Methods This retrospective observational study included neonates born between January 1, 2010 and March 31, 2019, whose mothers had been taking antipsychotic, antidepressant, sedative, or anticonvulsant medications. The outcome measures were HCs of NAS infants and controls. Results Of 159 infants, 33 (21%) were diagnosed with NAS. There was no maternal opioid use among mothers during pregnancy. The HCs in the NAS group were significantly smaller than those in the control group. The median z-scores for HC at birth were -0.20 and 0.29 in the NAS group and the control group, respectively (P = .011). The median HCs at birth were 33.0 and 33.5 cm in the NAS group and the control group, respectively. Multivariate analysis revealed that maternal antipsychotic drug use and selective serotonin reuptake inhibitors were independently associated with NAS (P < .001 and P = .004, respectively). Notably, benzodiazepine use and smoking were not independent risk factors. Conclusions The results suggest an association between maternal antipsychotic drug use and NAS, which was further associated with decreased HC. Careful monitoring of maternal drug use should be considered to improve fetal outcomes.
AB - Background No relationship has been reported between nonopiate neonatal abstinence syndrome (NAS) and anthropometric indices, including head circumference (HC). The purpose of this study was to determine the relationship between maternal nonopioid drug use and HC at birth in neonates with NAS. Methods This retrospective observational study included neonates born between January 1, 2010 and March 31, 2019, whose mothers had been taking antipsychotic, antidepressant, sedative, or anticonvulsant medications. The outcome measures were HCs of NAS infants and controls. Results Of 159 infants, 33 (21%) were diagnosed with NAS. There was no maternal opioid use among mothers during pregnancy. The HCs in the NAS group were significantly smaller than those in the control group. The median z-scores for HC at birth were -0.20 and 0.29 in the NAS group and the control group, respectively (P = .011). The median HCs at birth were 33.0 and 33.5 cm in the NAS group and the control group, respectively. Multivariate analysis revealed that maternal antipsychotic drug use and selective serotonin reuptake inhibitors were independently associated with NAS (P < .001 and P = .004, respectively). Notably, benzodiazepine use and smoking were not independent risk factors. Conclusions The results suggest an association between maternal antipsychotic drug use and NAS, which was further associated with decreased HC. Careful monitoring of maternal drug use should be considered to improve fetal outcomes.
KW - Modified Finnegan score
KW - anthropometric index
KW - maternal medication
KW - maternal mental health
KW - neonatal abstinence syndrome
UR - http://www.scopus.com/inward/record.url?scp=85089780124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089780124&partnerID=8YFLogxK
U2 - 10.1017/S1092852920001522
DO - 10.1017/S1092852920001522
M3 - Article
C2 - 32605668
AN - SCOPUS:85089780124
SN - 1092-8529
VL - 26
SP - 509
EP - 512
JO - CNS Spectrums
JF - CNS Spectrums
IS - 5
ER -